Sign In
  • Best Buys
  • Household Money
  • Banking & Borrowing
  • Mortgages & Home
  • Saving & Making Money
  • Rights, Scams & Politics
  • Motoring & Travel
  • Investing & Pensions
  • Savings & ISAs
  • Features
  • Compare

Companies making billions from COVID-19 vaccines

Firms profiting from COVID-19 vaccines
Vaxart and Emergent BioSolutions Inc.: doses TBC
Vaxart and Emergent BioSolutions Inc.: doses TBC
Valneva: 100 million confirmed doses before 2023
Inovio Pharmaceuticals: 100 million doses for China in 2021
CureVac: 280 million doses in 2021
CureVac: 280 million doses in 2021
Novavax: 418.7 million doses worldwide
Novavax: 418.7 million doses worldwide
CanSino Biologics Inc. and Beijing Institute of Biotechnology: 500 million doses worldwide annually
CanSino Biologics Inc. and Beijing Institute of Biotechnology: 500 million doses worldwide annually
GlaxoSmithKline and Sanofi: at least 732 million doses
GlaxoSmithKline and Sanofi: at least 732 million doses
Moderna Therapeutics: up to 1 billion doses worldwide in 2021
Moderna Therapeutics: up to 1 billion doses worldwide in 2021
Johnson & Johnson: 1 billion doses worldwide in 2021
Johnson & Johnson: 1 billion doses worldwide in 2021
Sinopharm: 1 billion doses worldwide in 2021
Sinopharm: 1 billion doses worldwide in 2021
Gamaleya Institute: 1.4 billion doses outside of Russia
Gamaleya Institute: 1.4 billion doses outside of Russia
Sinovac: 2 billion doses annually by June
Sinovac: 2 billion doses annually by June
Pfizer and BioNTech: 2.5 billion doses worldwide in 2021
Pfizer and BioNTech: 2.5 billion doses worldwide in 2021
University of Oxford and AstraZeneca: 3 billion doses worldwide
University of Oxford and AstraZeneca: 3 billion doses worldwide
1 of 27
WPA Pool/Pool/Getty Images

Firms profiting from COVID-19 vaccines

Manufacturing and distributing effective vaccinations against COVID-19 has been heralded as the only way out of the pandemic and the race is on to get as many doses produced as possible. With demand through the roof, producing these life-saving drugs has become a lucrative business, and the global coronavirus vaccine market will reach an enormous value of $35 billion (£25.1bn) in 2021 and is expected to grow to $42 billion (£30.6bn) by 2022, according to Arizton. But who is that money going to? Click or scroll through to find out which companies are making billions from producing COVID-19 vaccines, ranked in order of the number of doses they are set to produce.

Gallery view |
List View

Hannah Ward-Glenton

31 March 2021

Features

See more on this topic

Share the love